

Modulation of carbonic anhydrase activity and its appli

Expert Opinion on Therapeutic Patents

14, 667-702

DOI: 10.1517/13543776.14.5.667

Citation Report

#	ARTICLE	IF	CITATIONS
1	Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5435-5439.	1.0	43
2	Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5661-5666.	1.0	30
3	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5775-5780.	1.0	46
4	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral drug foscarnet. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5763-5767.	1.0	24
5	Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 6001-6006.	1.0	83
6	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5427-5433.	1.0	98
7	Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the methanoarchaeon <i>Methanobacterium thermoautotrophicum</i> (Cab) with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4563-4567.	1.0	49
8	Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5703-5707.	1.0	16
9	Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5781-5786.	1.0	29
10	Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 5769-5773.	1.0	26
11	Carbonic anhydrase inhibitors. Inhibition of <i>Plasmodium falciparum</i> carbonic anhydrase with aromatic sulfonamides: towards antimalarials with a novel mechanism of action?. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 483-489.	1.4	81
12	A physically interpretable quantum-theoretic QSAR for some carbonic anhydrase inhibitors with diverse aromatic rings, obtained by a new QSAR procedure. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2197-2211.	1.4	21
13	Carbonic anhydrase inhibitors: Inhibition of the human transmembrane isozyme XIV with a library of aromatic/heterocyclic sulfonamides. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6089-6093.	1.4	21
14	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbonate. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 567-571.	1.0	31
15	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 573-578.	1.0	60
16	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 579-584.	1.0	43
17	Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1149-1154.	1.0	29
18	Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 971-976.	1.0	145

#	ARTICLE	IF	CITATIONS
19	Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1683-1686.	1.0	25
20	Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1909-1913.	1.0	18
21	Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2315-2320.	1.0	176
22	Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4862-4866.	1.0	26
23	Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with l-histidine as a platform for the design of stronger activators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5136-5141.	1.0	99
24	Carbonic anhydrase inhibitors. Inhibition of red blood cell ostrich ( <i>Struthio camelus</i> ) carbonic anhydrase with a series of aromatic and heterocyclic sulfonamides. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2005, 20, 383-387.	2.5	8
25	Two developmental switches in GABAergic signalling: the K <sup>+</sup> -Cl <sup>-</sup> cotransporter KCC2 and carbonic anhydrase CAVII. <i>Journal of Physiology</i> , 2005, 562, 27-36.	1.3	357
26	Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 367-372.	1.0	56
27	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanyl scaffolds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2359-2364.	1.0	25
28	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 2347-2352.	1.0	70
29	Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 3102-3108.	1.0	137
30	Carbonic anhydrase inhibitors: Inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5192-5196.	1.0	24
31	Carbonic anhydrase inhibitors: CA IX selective inhibitors incorporating aromatic or heterocyclic sulfonamide. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 233-236.	2.4	1
32	Carbonic Anhydrase Inhibitors: Stacking with Phe131 Determines Active Site Binding Region of Inhibitors As Exemplified by the X-ray Crystal Structure of a Membrane-Impermeant Antitumor Sulfonamide Complexed with Isozyme II. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5721-5727.	2.9	157
33	Molecular Basis for the Origin of Differential Spectral and Binding Profiles of Dansylamide with Human Carbonic Anhydrase I and II. <i>Biochemistry</i> , 2005, 44, 3673-3682.	1.2	14
34	Carbonic Anhydrase Inhibitors. The Mitochondrial Isozyme VB as a New Target for Sulfonamide and Sulfamate Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7860-7866.	2.9	179
35	Tumor-associated Carbonic Anhydrases and Their Clinical Significance. <i>Advances in Clinical Chemistry</i> , 2006, 42, 167-216.	1.8	124
36	Carbonic Anhydrase Activators. Activation of Isoforms I, II, IV, VA, VII, and XIV with l- and d-Phenylalanine and Crystallographic Analysis of Their Adducts with Isozyme II: Stereospecific Recognition within the Active Site of an Enzyme and Its Consequences for the Drug Design. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3019-3027.	2.9	128

#	ARTICLE	IF	CITATIONS
37	Carbonic anhydrase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozymes I and II with some 1,3,4-oxadiazole-thiols. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2006, 21, 351-359.	2.5	7
38	Carbonic anhydrase inhibitors. N-Cyanomethylsulfonamides—a new zinc binding group in the design of inhibitors targeting cytosolic and membrane-anchored isoforms. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2006, 21, 477-481.	2.5	3
39	Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2006, 21, 563-568.	2.5	19
40	Carbonic Anhydrase Inhibitors: Clash with Ala65 as a Means for Designing Inhibitors with Low Affinity for the Ubiquitous Isozyme II, Exemplified by the Crystal Structure of the Topiramate Sulfamide Analogue. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7024-7031.	2.9	147
41	Carbonic Anhydrase Inhibitors: DNA Cloning and Inhibition Studies of the $\beta$ -Carbonic Anhydrase from <i>Helicobacter pylori</i> , A New Target for Developing Sulfonamide and Sulfamate Gastric Drugs. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2117-2126.	2.9	154
42	Carbonic anhydrase inhibitors and activators and their use in therapy. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1627-1664.	2.4	158
43	Examination of Two Independent Kinetic Assays for Determining the Inhibition of Carbonic Anhydrases I and II: Structure?Activity Comparison of Sulfamates and Sulfamides. <i>Chemical Biology and Drug Design</i> , 2006, 68, 113-119.	1.5	14
44	Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated $\beta$ -carbonic anhydrase from <i>Helicobacter pylori</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2182-2188.	1.0	42
45	N-Hydroxyurea—a versatile zinc binding function in the design of metalloenzyme inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4316-4320.	1.0	35
46	QSAR study on para-substituted aromatic sulfonamides as carbonic anhydrase II inhibitors using topological information indices. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1108-1114.	1.4	63
47	Carbonic anhydrase inhibitors: Transepithelial transport of thioureido sulfonamide inhibitors of the cancer-associated isozyme IX is dependent on efflux transporters. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 2418-2427.	1.4	18
48	Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II selective inhibitor celecoxib. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 437-442.	1.0	93
49	Carbonic anhydrase inhibitors: Inhibition of the cytosolic human isozyme VII with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3139-3143.	1.0	26
50	Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to human isoform II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 6204-6208.	1.0	32
51	Carbonic Anhydrase Activators. Activation of Isozymes I, II, IV, VA, VII, and XIV with L- and D-Histidine and Crystallographic Analysis of Their Adducts with Isoform II: Engineering Proton-Transfer Processes within the Active Site of an Enzyme. <i>Chemistry - A European Journal</i> , 2006, 12, 7057-7066.	1.7	131
52	Therapeutic potential of sulfamides as enzyme inhibitors. <i>Medicinal Research Reviews</i> , 2006, 26, 767-792.	5.0	173
53	Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles. <i>Current Pharmaceutical Design</i> , 2006, 12, 3459-3465.	0.9	57
54	The sulfamide motif in the design of enzyme inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 27-47.	2.4	74

#	ARTICLE	IF	CITATIONS
55	Therapeutic applications of the carbonic anhydrase inhibitors. <i>Therapy: Open Access in Clinical Medicine</i> , 2007, 4, 355-378.	0.2	29
56	Reconstitution of carbonic anhydrase activity of the cell-surface-binding protein of vaccinia virus. <i>Biochemical Journal</i> , 2007, 407, 61-67.	1.7	10
57	Structural Analysis of Charge Discrimination in the Binding of Inhibitors to Human Carbonic Anhydrases I and II. <i>Journal of the American Chemical Society</i> , 2007, 129, 5528-5537.	6.6	62
58	Carbonic Anhydrase Inhibitors. DNA Cloning, Characterization, and Inhibition Studies of the Human Secretory Isoform VI, a New Target for Sulfonamide and Sulfamate Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 381-388.	2.9	88
59	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2298-2311.	1.4	44
60	Carbonic anhydrase activators: The first activation study of the human secretory isoform VI with amino acids and amines. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 5351-5357.	1.4	52
61	QSAR studies on the activation of the human carbonic anhydrase cytosolic isoforms I and II and secretory isozyme VI with amino acids and amines. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6501-6509.	1.4	4
62	Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6975-6984.	1.4	78
63	Carbonic anhydrase inhibitors: The inhibition profiles of the human mitochondrial isoforms VA and VB with anions are very different. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6742-6747.	1.4	17
64	Carbonic anhydrase activators: An activation study of the human mitochondrial isoforms VA and VB with amino acids and amines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1336-1340.	1.0	44
65	Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1726-1731.	1.0	38
66	Carbonic anhydrase inhibitors: Inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1538-1543.	1.0	29
67	Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1532-1537.	1.0	35
68	Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose- $\epsilon$ -thioureido tails. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2685-2691.	1.0	48
69	Carbonic anhydrase activators: Activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4107-4112.	1.0	48
70	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5086-5090.	1.0	41
71	Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 2210-2215.	1.0	48
72	Carbonic anhydrase inhibitors. Inhibition studies of the human secretory isoform VI with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1037-1042.	1.0	33

#	ARTICLE	IF	CITATIONS
73	Carbonic anhydrase inhibitors: Inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3933-3940.	1.4	29
74	Carbonic anhydrase activators: Activation of the human tumor-associated isozymes IX and XII with amino acids and amines. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3530-3536.	1.4	45
75	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2567-2573.	1.0	67
76	Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4282-4286.	1.0	10
77	Carbonic anhydrase inhibitors: Inhibition of the $\hat{\Gamma}^2$ -class enzymes from the fungal pathogens <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> with simple anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5066-5070.	1.0	98
78	Carbonic anhydrase inhibitors. Inhibition of the $\hat{\Gamma}^2$ -class enzyme from the yeast <i>Saccharomyces cerevisiae</i> with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6327-6331.	1.0	47
79	Carbonic anhydrase inhibitors: The X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2669-2674.	1.0	35
80	Inhibition of Carbonic Anhydrases with Glycosyltriazole Benzene Sulfonamides. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1945-1953.	2.9	77
81	Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited- old leads for new applications?. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 2499.	1.5	88
82	Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2008, 23, 271-276.	2.5	27
83	Carbonic Anhydrase-II Inhibition. What are the True Enzyme's Inhibitory Properties of the Sulfamide Cognate of Topiramate?. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2518-2521.	2.9	9
84	Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX with some 1,3,4-oxadiazole- and 1,2,4-triazole-thiols. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2008, 23, 101-107.	2.5	23
85	Differential <i>in vitro</i> inhibition effects of some antibiotics on tumor associated carbonic anhydrase isozymes of hCA-IX and hCA-XII. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2008, 23, 579-585.	2.5	6
86	Carbonic Anhydrase Activation and the Drug Design. <i>Current Pharmaceutical Design</i> , 2008, 14, 708-715.	0.9	81
87	The Alpha-Carbonic Anhydrase from the Malaria Parasite and its Inhibition. <i>Current Pharmaceutical Design</i> , 2008, 14, 631-640.	0.9	74
90	Quantitative structure-activity relationship (QSAR) studies on a series of 1,3,4-thiadiazole-2-thione derivatives as tumor-associated carbonic anhydrase IX inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2009, 24, 722-729.	2.5	8
91	Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 74, 164-175.	1.5	97
92	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1214-1221.	1.4	61

#	ARTICLE	IF	CITATIONS
93	Carbonic anhydrase inhibitors: Inhibition of the $\hat{\Gamma}^2$ -class enzyme from the yeast <i>Saccharomyces cerevisiae</i> with sulfonamides and sulfamates. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1158-1163.	1.4	86
94	Carbonic anhydrase inhibitors. The nematode $\hat{\Gamma}^{\pm}$ -carbonic anhydrase of <i>Caenorhabditis elegans</i> CAH-4b is highly inhibited by 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 3212-3215.	1.4	16
95	Carbonic anhydrase inhibitors. Inhibition of the $\hat{\Gamma}^2$ -class enzymes from the fungal pathogens <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> with aliphatic and aromatic carboxylates. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2654-2657.	1.4	69
96	A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode $\hat{\Gamma}^{\pm}$ -carbonic anhydrases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1371-1375.	1.0	18
97	Carbonic anhydrase activators: Activation of the $\hat{\Gamma}^2$ -carbonic anhydrase Nce103 from the yeast <i>Saccharomyces cerevisiae</i> with amines and amino acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1662-1665.	1.0	21
98	Carbonic anhydrase inhibitors. Inhibition of the $\hat{\Gamma}^2$ -class enzyme from the pathogenic yeast <i>Candida glabrata</i> with anions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4802-4805.	1.0	45
99	Carbonic anhydrase inhibitors; Fluorinated phenyl sulfamates show strong inhibitory activity and selectivity for the inhibition of the tumor-associated isozymes IX and XII over the cytosolic ones I and II. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 5082-5085.	1.0	12
100	CP-MLR directed QSAR study of carbonic anhydrase inhibitors: sulfonamide and sulfamate inhibitors. <i>Open Chemistry</i> , 2009, 7, 909-922.	1.0	5
101	Carbonic Anhydrase Inhibitors. Comparison of Chlorthalidone and Indapamide X-ray Crystal Structures in Adducts with Isozyme II: When Three Water Molecules and the Keto $\rightleftharpoons$ Enol Tautomerism Make the Difference. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 322-328.	2.9	56
102	Carbonic Anhydrase Inhibitors. Comparison of Aliphatic Sulfamate/Bis-sulfamate Adducts with Isozymes II and IX as a Platform for Designing Tight-Binding, More Isoform-Selective Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5990-5998.	2.9	21
105	Carbonic anhydrase activators. The first activation study of a coral secretory isoform with amino acids and amines. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2300-2303.	1.4	28
106	Bidentate Zinc Chelators for $\hat{\Gamma}^{\pm}$ -Carbonic Anhydrases that Produce a Trigonal Bipyramidal Coordination Geometry. <i>ChemMedChem</i> , 2010, 5, 1609-1615.	1.6	27
107	Synthesis, characterization, antibacterial activities and carbonic anhydrase enzyme inhibitor effects of new arylsulfonylhydrazone and their Ni(II), Co(II) complexes. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2010, 75, 121-126.	2.0	36
108	Carbonic anhydrase inhibitors. The $\hat{\Gamma}^2$ -carbonic anhydrases from the fungal pathogens <i>Cryptococcus neoformans</i> and <i>Candida albicans</i> are strongly inhibited by substituted-phenyl-1H-indole-5-sulfonamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2508-2511.	1.0	27
109	Carbonic anhydrase activators: Activation of the $\hat{\Gamma}^2$ -carbonic anhydrase from the pathogenic yeast <i>Candida glabrata</i> with amines and amino acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1701-1704.	1.0	19
110	Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4376-4381.	1.0	70
111	Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 3656-3661.	2.6	25
112	Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII. <i>Current Medicinal Chemistry</i> , 2010, 17, 1516-1526.	1.2	100

#	ARTICLE	IF	CITATIONS
113	Carbonic anhydrase inhibitors: Gd(III) complexes of DOTA- and TETA-sulfonamide conjugates targeting the tumor associated carbonic anhydrase isozymes IX and XII. <i>New Journal of Chemistry</i> , 2010, 34, 2139.	1.4	5
114	Interfering with pH regulation in tumours as a therapeutic strategy. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 767-777.	21.5	1,340
115	Adaptive variable-weighted support vector machine as optimized by particle swarm optimization algorithm with application of QSAR studies. <i>Talanta</i> , 2011, 84, 13-18.	2.9	16
116	Malaria parasite carbonic anhydrase: inhibition of aromatic/heterocyclic sulfonamides and its therapeutic potential. <i>Asian Pacific Journal of Tropical Biomedicine</i> , 2011, 1, 233-242.	0.5	35
117	Carbonic anhydrase inhibitors. Inhibition of the $\beta$ -class enzymes from the fungal pathogens <i>Candida albicans</i> and <i>Cryptococcus neoformans</i> with branched aliphatic/aromatic carboxylates and their derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2521-2526.	1.0	33
118	Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs. <i>Current Medicinal Chemistry</i> , 2012, 19, 821-830.	1.2	50
119	DNA Cloning, Characterization, and Inhibition Studies of an $\alpha$ -Carbonic Anhydrase from the Pathogenic Bacterium <i>Vibrio cholerae</i> . <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10742-10748.	2.9	103
120	The first activation study of a bacterial carbonic anhydrase (CA). The thermostable $\alpha$ -CA from <i>Sulfurihydrogenibium yellowstonense</i> YO3AOP1 is highly activated by amino acids and amines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6324-6327.	1.0	73
121	Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII. <i>European Journal of Medicinal Chemistry</i> , 2012, 56, 282-291.	2.6	12
122	Structural characterization of zinc bicarbonate compounds relevant to the mechanism of action of carbonic anhydrase. <i>Chemical Science</i> , 2012, 3, 2015.	3.7	58
123	Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. <i>World Journal of Clinical Oncology</i> , 2012, 3, 98.	0.9	79
124	Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?. <i>Chemical Reviews</i> , 2012, 112, 4421-4468.	23.0	1,056
125	Glycosidic carbonic anhydrase IX inhibitors: A sweet approach against cancer. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1419-1426.	1.4	58
126	Thermodynamic study of proton transfer in carbonic anhydrase/activator complex: A quantum mechanical approach. <i>Computational and Theoretical Chemistry</i> , 2013, 1022, 121-129.	1.1	5
127	The extreme- $\alpha$ -carbonic anhydrase (CA) from <i>Sulfurihydrogenibium azorense</i> , the fastest CA known, is highly activated by amino acids and amines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1087-1090.	1.0	55
128	Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an $\alpha$ -Carbonic Anhydrase from <i>Trypanosoma cruzi</i> , the Causative Agent of Chagas Disease. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1761-1771.	2.9	89
129	Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005 – 2013). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 681-691.	2.4	252
130	Structural effect of phenyl ring compared to thiadiazole based adamantyl-sulfonamides on carbonic anhydrase inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2314-2318.	1.4	20



#	ARTICLE	IF	CITATIONS
131	Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013). Expert Opinion on Therapeutic Patents, 2013, 23, 737-749.	2.4	226
132	Cloning, Characterization, and Inhibition Studies of a $\hat{\text{I}}^2$ -Carbonic Anhydrase from <i>Leishmania donovani</i> chagasi, the Protozoan Parasite Responsible for Leishmaniasis. Journal of Medicinal Chemistry, 2013, 56, 7372-7381.	2.9	87
133	Carbonic Anhydrase IX: From Biology to Therapy. Cancer Drug Discovery and Development, 2014, , 121-153.	0.2	4
134	Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII. European Journal of Medicinal Chemistry, 2014, 82, 47-55.	2.6	18
135	Carbonic Anhydrase II as Target for Drug Design. , 2015, , 51-90.		2
136	Tumor-Associated Carbonic Anhydrases IX and XII. , 2015, , 169-205.		12
137	Spirobisnaphthalenes effectively inhibit carbonic anhydrase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 31, 1-5.	2.5	24
138	Betulinic acid derived hydroxamates and betulin derived carbamates are interesting scaffolds for the synthesis of novel cytotoxic compounds. European Journal of Medicinal Chemistry, 2015, 106, 194-210.	2.6	38
139	Synthesis and evaluation of new benzodioxole-based dithiocarbamate derivatives as potential anticancer agents and hCA-I and hCA-II inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 190-196.	2.6	33
140	Carbonic anhydrase inhibitors as diuretics. , 2019, , 287-309.		0
141	New 2-hydroxyethyl substituted N-Heterocyclic carbene precursors: Synthesis, characterization, crystal structure and inhibitory properties against carbonic anhydrase and xanthine oxidase. Journal of Molecular Structure, 2019, 1184, 487-494.	1.8	26
142	Morin attenuates ifosfamide-induced neurotoxicity in rats via suppression of oxidative stress, neuroinflammation and neuronal apoptosis. NeuroToxicology, 2020, 76, 126-137.	1.4	73
143	Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?. Medicinal Research Reviews, 2020, 40, 2485-2565.	5.0	154
144	Synthesis of new series of thiazol-2(3H)-ylideneamino)benzenesulfonamide derivatives as carbonic anhydrase inhibitors. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22596.	1.4	7
145	Evaluation of some thiophene-based sulfonamides as potent inhibitors of carbonic anhydrase I and II isoenzymes isolated from human erythrocytes by kinetic and molecular modelling studies. Pharmacological Reports, 2020, 72, 1738-1748.	1.5	14
146	DFT based QSARs for inhibitory activity of coumarins towards tumor-associated isoform (CA XII) of carbonic anhydrases. Journal of Molecular Structure, 2020, 1208, 127844.	1.8	2
147	Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): <i>in vitro</i> and <i>in vivo</i> studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 954-963.	2.5	11
148	Synthesis and Enzyme Inhibitory Activity of Novel Pyridine-2,6-dicarboxamides Bearing Primary Sulfonamide Groups. Russian Journal of Organic Chemistry, 2019, 55, 1951-1956.	0.3	6

#	ARTICLE	IF	CITATIONS
149	In vitro Carbonic Anhydrase Inhibitory Effects of The Extracts of Satureja cuneifolia. Turkish Journal of Agricultural and Natural Sciences, 0, , .	0.1	1
150	The synthesis and characterization of some new diazoamino derivatives. Chemical Industry and Chemical Engineering Quarterly, 2010, 16, 89-95.	0.4	0
151	Inhibition of Carbonic Anhydrase, Acetylcholinesterase and Butyrylcholinesterase by BisPMB, A Synthetic Analogue of Ajoene. Journal of the Turkish Chemical Society, Section A: Chemistry, 0, , 143-148.	0.4	2
152	Recent advances in the design and synthesis of small molecule carbonic anhydrase IX inhibitors. Current Topics in Medicinal Chemistry, 2022, 22, .	1.0	1
153	In vitro antioxidant activity and carbonic anhydrase inhibitory features of Ferula communis extracts. International Journal of Agriculture Environment and Food Sciences, 0, , 592-599.	0.2	3
154	1,5-Benzodiazepines as a platform for the design of carbonic anhydrase inhibitors. Archiv Der Pharmazie, 2022, 355, 2100405.	2.1	3
155	Identification of the Inhibition Effects of Some Natural Antiproliferative Agents on CA-I, CA-II, and AChE Activities Isolated from Human Erythrocytes by Kinetic and Molecular Docking Studies. Russian Journal of Bioorganic Chemistry, 2022, 48, 720-730.	0.3	3
156	Coumarin and Piperazine Conjugates as Selective Inhibitors of the Tumor-associated Carbonic Anhydrase IX and XII Isoforms. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 1184-1191.	0.9	3